BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module
BullFrog AI (NASDAQ: BFRG) announced the expansion of its internal sales organization to accelerate the commercialization of its clinical trial optimization solutions, including the recently launched bfPREP™ module. This expansion complements their existing partnership with Sygnature Discovery for BullFrog Data Networks™.
The dual-pronged commercial strategy includes: 1) Sygnature partnership focusing on selling target selection solutions to global biopharma clients, and 2) Direct sales team marketing bfPREP and clinical trial optimization tools. The bfPREP module, initially developed for Eleison Pharmaceuticals collaboration, standardizes diverse clinical trial data into analyzable formats within days.
- Expansion of internal sales organization to accelerate revenue growth
- Strategic partnership with Sygnature Discovery enhances market reach
- Dual-pronged commercial strategy covers full drug development lifecycle
- bfPREP module offers rapid data standardization capabilities
- None.
Insights
BullFrog AI's sales team expansion strategically positions the company to accelerate revenue through direct commercialization of its clinical trial optimization technologies.
BullFrog AI's announcement signals a strategic commercial expansion designed to accelerate market penetration for its AI-powered clinical trial optimization platforms. The company is now pursuing a dual-track commercialization strategy—leveraging its partnership with Sygnature Discovery for target selection solutions while building internal sales capacity focused on trial optimization technologies like bfPREP.
The bfPREP module addresses a critical industry pain point by transforming diverse, unstructured clinical trial data into standardized, analyzable formats within days—a process that typically requires significant time and resources. This capability enables pharmaceutical companies to extract value from legacy and siloed data that might otherwise remain unusable.
This commercial expansion represents a vertical integration of BullFrog's offering. The company can now deliver value across the drug development lifecycle: from early-stage target discovery (through Sygnature) to clinical trial optimization (through direct sales). This comprehensive approach differentiates BullFrog from point-solution providers in the highly competitive AI drug discovery market.
The timing is strategically significant as pharmaceutical companies face mounting pressure to reduce the
While the press release doesn't provide specific revenue projections or hiring targets, the emphasis on "accelerated revenue growth" suggests management expects this expansion to meaningfully impact the company's financial trajectory in the near term.
GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, including its recently launched bfPREP™ module.
The expansion of BullFrog AI’s in-house sales capabilities complements the Company’s recent commercial rollout with Sygnature Discovery, which is focused on selling BullFrog Data Networks™ target selection solutions to global biopharma clients. By strengthening its direct sales organization, BullFrog AI is positioned to accelerate adoption of its trial-focused platforms, including bfPREP, among pharmaceutical and biotechnology companies.
“While our collaboration with Sygnature positions BullFrog Data Networks™ as a powerful target discovery solution for global biopharma R&D, the expansion of our sales team strengthens our ability to directly market and deliver bfPREP and clinical trial optimization tools to drug developers worldwide,” said Vin Singh, Founder and CEO of BullFrog AI. “This dual-pronged strategy broadens our commercial reach and ensures we are capturing opportunities across the full drug development lifecycle.”
The bfPREP module, originally developed to support BullFrog AI’s collaboration with Eleison Pharmaceuticals, is purpose-built to handle the scale and complexity of diverse clinical trial data. From legacy records and siloed datasets to unstructured documents, bfPREP transforms raw information into standardized, analyzable formats at scale with results achievable in a matter of days.
BullFrog AI’s expanded sales team is working to accelerate adoption of bfPREP, and the Company’s broader suite of trial optimization solutions. Once data has been standardized through bfPREP, platforms such as bfLEAP® can be applied to uncover patient subgroups, inform trial design, and support more precise execution. By aligning these capabilities under a focused commercial strategy, BullFrog AI offers sponsors an end-to-end approach to improving trial efficiency and outcomes.
“Demand for technologies that reduce risk and cost in clinical development has never been higher,” added Mr. Singh. “By expanding our internal sales capacity, we are positioning BullFrog AI to accelerate revenue growth and create lasting value for our shareholders while continuing to advance our long-term vision of transforming drug development with AI.”
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™ and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
What is BullFrog AI's (BFRG) bfPREP™ module and what does it do?
How is BullFrog AI (BFRG) expanding its commercial strategy in 2025?
What is the partnership between BullFrog AI and Sygnature Discovery?
How does BullFrog AI's technology improve clinical trials?
